SOURCE: MMRGlobal, Inc.

MMRGlobal, Inc.

May 29, 2014 08:15 ET

Court Limits Claim Construction in MyMedicalRecords Patent Litigation

LOS ANGELES, CA--(Marketwired - May 29, 2014) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), today announced that on May 28th, the United States District Court, Central District of California issued a significant order in the MyMedicalRecords, Inc. patent cases against Quest Diagnostics, Inc., WebMD Health Corp. et al, Jardogs, LLC and Allscripts Healthcare Solutions, Inc. The order was issued in advance of an upcoming Markman hearing and pertains to scheduling of a joint technology tutorial and the Court's review of a Statement of Joint Claim Construction filed on May 27, 2014. As part of its review, the Court reminded the parties of limitation of terms for purposes of claims construction. The Court found that the joint report included large portions of the claim language, which the Court said was impermissible and improper. Therefore, the Court struck the deficient statement and ordered the parties to resubmit a statement by June 5th, 2014. According to Robert H. Lorsch, MMRGlobal CEO, "MMR welcomed the Court's order and looks forward to the filing of a fully compliant Amended Joint Claim Construction and Prehearing statement. We also look forward to completion of the Markman process including the joint technology tutorial only weeks away."

According to Ted Ward, an attorney for MMRGlobal, "MMR views this order as a significant development in these patent cases, demonstrating the Court's preference in streamlining this litigation and forcing the parties to identify and narrow the case to the most important issues."

The Court also ordered that the technology tutorial hearing, originally scheduled for July 2, 2014, will now take place on June 18, 2014. The Court expects the parties to meet and confer and present a tutorial that explains the technology disclosed in the patents. The tutorial should provide a neutral objective overview of the technology. (Additional information on filings pertaining to this case can be found at

MyMedicalRecords, Inc.'s global health information technology patent portfolio currently includes 11 U.S. patents: U.S. Patent Nos. 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883; 8,626,532; 8,645,161 and 8,725,537, which collectively includes over 275 issued claims, along with additional applications and continuation applications pending. MMR has also received issued patents and has pending applications in 11 other countries or regional authorities of commercial interest including Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and Europe.

Although MMR's primary business is as a provider and licensor of health IT products and services, MMRGlobal also has a portfolio of biotech patents. These pertain to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the U.S., Mexico, Australia and South Korea, with patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea, and additional patents pertaining to its B-cell idiotype vaccine worldwide.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of MMR's products and services at Follow us at and

Forward-Looking Statements
 All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information